GLOBUS MEDICAL INC GMED

Globus Medical, Inc. es una empresa de dispositivos médicos. La empresa se enfoca principalmente en implantes que promueven la curación en pacientes con trastornos musculoesqueléticos. La empresa agrupa sus productos en dos categorías: Soluciones Musculoesqueléticas y Tecnologías Habilitadoras. Sus Soluciones Musculoesqueléticas consisten principalmente en dispositivos implantables, biológicos, accesorios e instrumentos quirúrgicos utilizados en una amplia gama de procedimientos espinales, ortopédicos y neuroquirúrgicos. Sus Tecnologías Habilitadoras están compuestas por soluciones de imagen, navegación y robótica (INR) para cirugía asistida, que son sistemas inteligentes asistidos por computadora diseñados para mejorar las capacidades de un cirujano y, en última instancia, mejorar la atención al paciente y reducir la exposición a la radiación para todos los involucrados. Sus soluciones INR incluyen la plataforma ExcelsiusGPS, que es un sistema de guía y navegación robótica que apoya procedimientos mínimamente invasivos y abiertos con aplicaciones de colocación de tornillos y espaciadores intervertebrales.

• Zacks Investment Research 5 oct

  Reasons to Retain Doximity Stock in Your Portfolio for Now

  Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth.

  

• Zacks Investment Research 5 oct

  Here's Why Globus Medical (GMED) is a Strong Value Stock

  Zacks presents its investment research tools including Thematic Investment Screens covering 37 themes and the Zacks Rank stock-rating system combined with Style Scores (Value, Growth, Momentum, VGM). The article highlights how the Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, outperforming the S&P 500. Globus Medical (GMED) is featured as a #1 Strong Buy with attractive valuation metrics.

  

• Zacks Investment Research 1 oct

  Neogen Stock Rallies 83% YTD: What's Driving the Surge?

  Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

  

• Zacks Investment Research 30 sept

  Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

  Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.

  

• Zacks Investment Research 30 sept

  10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

  10x Genomics has begun commercial shipments of Atera, its next-generation spatial biology platform, with booked orders exceeding 40 instruments and demand surpassing initial 2026 expectations. The platform enables whole-transcriptome analysis with single-cell sensitivity and is gaining traction across academic, translational, and biopharma research. The global spatial transcriptomics market is projected to reach $495.2 million by 2026 with a 14.7% CAGR through 2033.